The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
 
Saranya Chumsri
Consulting or Advisory Role - Eisai; Immunomedics; Novartis; Puma Biotechnology; Syndax
Research Funding - Array BioPharma; Merck
 
Mei-Yin Polley
No Relationships to Disclose
 
Pulkit Mathur
No Relationships to Disclose
 
Aline Reis
No Relationships to Disclose
 
Kathleen S. Tenner
No Relationships to Disclose
 
Morgan Weidner
No Relationships to Disclose
 
Pooja Advani
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Edith A. Perez
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
Consulting or Advisory Role - Daiichi Sankyo; Puma Biotechnology; Seagen
Research Funding - bioTheranostics (Inst); Genentech (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); LabCorp (Inst); Novartis (Inst)
 
Keith L. Knutson
No Relationships to Disclose